The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Inhibition of Hemangiogenesis and Lymphangiogenesis after Normal-Risk Corneal Transplantation by Neutralizing VEGF Promotes Graft Survival
Open accessAbstract
PURPOSE: To evaluate the occurrence and time course of hem- and lymphangiogenesis after normal-risk corneal transplantation in the mouse model and to test whether pharmacologic strategies inhibiting both processes improve long-term graft survival. METHODS: Normal-risk allogeneic (C57BL/6 to BALB/c) and syngeneic (BALB/c to BALB/c) corneal transplantations were performed and occurrence and time course of hem- and lymphangiogenesis after keratoplasty was observed, by using double immunofluorescence of corneal flatmounts (with CD31 as a panendothelial and LYVE-1 as a lymphatic vascular endothelium-specific marker). A molecular trap designed to eliminate VEGF-A (VEGF Trap(R1R2); 12.5 mg/kg) was tested for its ability to inhibit both processes after keratoplasty and to promote long-term graft survival (intraperitoneal injections on the day of surgery and 3, 7, and 14 days later). RESULTS: No blood or lymph vessels were detectable immediately after normal-risk transplantation in either donor or host cornea, but hem- and lymphangiogenesis were clearly visible at day 3 after transplantation. Both vessel types reached donor tissue at 1 week after allografting and similarly after syngeneic grafting. Early postoperative trapping of VEGF-A significantly reduced both hem- and lymphangiogenesis and significantly improved long-term graft survival (78% vs. 40%; P < 0.05). CONCLUSIONS: There is concurrent, VEGF-A-dependent hem- and lymphangiogenesis after normal-risk keratoplasty within the preoperatively avascular recipient bed. Inhibition of hem- and lymphangiogenesis (afferent and efferent arm of an immune response) after normal-risk corneal transplantation improves long-term graft survival, establishing early postoperative hem- and lymphangiogenesis as novel risk factors for graft rejection even in low-risk eyes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Self-citationLYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan
Banerji, S., Ni, J., Wang, S.-X., Clasper, S., Su, J., Tammi, R., Jones, M., & Jackson, D. G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.144.4.789 · Cited by 1,583
Self-citationCursiefen, C., Chen, L., Borges, L. P., Jackson, D. G., Cao, J., Radziejewski, C. H., D'Amore, P. A., Dana, M. R., Wiegand, S. J., & Streilein, J. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420465 · Cited by 1,059
Self-citationVeikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T. V., Kubo, H., Thurston, G., McDonald, D. M., Achen, M. G., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1223 · Cited by 663
Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021244 · Cited by 559
Maguire, M. G., Stark, W. J., Gottsch, J. D., Stulting, R. D., Sugar, A., Fink, N. E., & Schwartz, A. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31138-9 · Cited by 466
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
Karkkainen, M. J., & Petrova, T. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203855 · Cited by 427
Kubo, H., Cao, R., Bräkenhielm, E., Mäkinen, T., Cao, Y., & Alitalo, K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062040199 · Cited by 305
SONODA, Y., & STREILEIN, J. W. (1992) · Transplantation · doi:10.1097/00007890-199210000-00026 · Cited by 297
Self-citation
Cited by
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis
Bock, F., Onderka, J., Dietrich, T., Bachmann, B., Kruse, F. E., Paschke, M., Zahn, G., & Cursiefen, C. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0570 · Cited by 320
Self-citationHos, D., Matthaei, M., Bock, F., Maruyama, K., Notara, M., Clahsen, T., Hou, Y., Le, V. N. H., Salabarria, A.-C., Horstmann, J., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.001 · Cited by 303
Self-citationDietrich, T., Bock, F., Yuen, D., Hos, D., Bachmann, B. O., Zahn, G., Wiegand, S., Chen, L., & Cursiefen, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903180 · Cited by 292
Self-citationDendritic cell physiology and function in the eye
Forrester, J. V., Xu, H., Kuffová, L., Dick, A. D., & McMenamin, P. G. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00873.x · Cited by 195
Nork, T. M. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.210 · Cited by 48
Antiangiogenesis Effect of Albendazole on the Cornea
Cho, Y. K., Shin, E. Y., Uehara, H., & Ambati, B. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0103 · Cited by 7
Metadata
- Authors
- Cursiefen, C., Cao, J., Chen, L., Liu, Y., Maruyama, K., Jackson, D., Kruse, F. E., Wiegand, S. J., Dana, M. R., & Streilein, J. W.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2004-08-01
- Volume
- 45
- Issue
- 8
- Pages
- 2666
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2022985798
- Cited by
- 329
- References
- 21
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
